We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Convey Health Solutions Holdings Inc | NYSE:CNVY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.51 | 0 | 01:00:00 |
| | |
Page
|
| |||
SUMMARY | | | | | 1 | | |
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 11 | | | |
| | | | 16 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 23 | | | |
| | | | 23 | | | |
| | | | 33 | | | |
| | | | 33 | | | |
| | | | 38 | | | |
| | | | 38 | | | |
| | | | 46 | | | |
| | | | 48 | | | |
| | | | 49 | | | |
| | | | 49 | | | |
| | | | 52 | | | |
| | | | 53 | | | |
| | | | 53 | | | |
| | | | 54 | | | |
| | | | 54 | | |
| | |
Page
|
| |||
| | | | 58 | | | |
| | | | 59 | | | |
| | | | 59 | | | |
| | | | 59 | | | |
| | | | 61 | | | |
| | | | 62 | | | |
| | | | 63 | | | |
| | | | 63 | | | |
| | | | 63 | | | |
| | | | 63 | | | |
| | | | 63 | | | |
| | | | 64 | | | |
| | | | 65 | | | |
| | | | 66 | | | |
| | | | 66 | | | |
| | | | 68 | | | |
| | | | 71 | | | |
| | | | 71 | | | |
| | | | 72 | | | |
| | | | 74 | | | |
| | | | 74 | | | |
| | | | 75 | | | |
| | | | 77 | | | |
| | | | 79 | | | |
| | | | 80 | | | |
| | | | 81 | | | |
| | | | 82 | | | |
| | | | 82 | | | |
| | | | 82 | | | |
| | | | 83 | | | |
| | | | 85 | | | |
| | | | 87 | | | |
| | | | 88 | | | |
| | | | 93 | | | |
| | | | 95 | | | |
| | | | A-1 | | | |
| | | | B-1 | | | |
| | | | C-1 | | | |
| | | | D-1 | | |
Company
|
| |
EV / 2023E
EBITDA Multiple |
|
Allscripts Healthcare Solutions, Inc.(1)
|
| |
7.5x
|
|
Computer Programs and Systems, Inc.
|
| |
9.0x
|
|
Evolent Health, Inc.
|
| |
21.9x
|
|
HealthStream Inc.
|
| |
9.5x
|
|
Health Catalyst, Inc.
|
| |
N/A
|
|
MultiPlan Corporation
|
| |
8.9x
|
|
Nextgen Healthcare, Inc.
|
| |
10.1x
|
|
Omnicell, Inc.
|
| |
17.3x
|
|
Phreesia, Inc.
|
| |
N/A
|
|
Premier, Inc.
|
| |
8.1x
|
|
R1 RCM Inc.
|
| |
15.1x
|
|
Signify Health, Inc.
|
| |
11.1x
|
|
Average (Selected Companies)
|
| |
11.8x
|
|
Median (Selected Companies)
|
| |
9.8x
|
|
Date Announced
|
| |
Target
|
| |
Acquiror
|
| |
Premium to
Unaffected |
| |
Premium to
52-wk High |
|
November 2021 | | | Independence Holding Company | | | Geneve Holdings, Inc. | | |
35.7%
|
| |
18.7%
|
|
October 2020 | | | Eidos Therapeutics, Inc. | | | BridgeBio Pharma, Inc. | | |
41.0%
|
| |
11.6%
|
|
August 2020 | | | Akcea Therapeutics, Inc. | | |
Ionis Pharmaceuticals, Inc.
|
| |
59.5%
|
| |
(19.2)%
|
|
August 2020 | | | Hudson Ltd. | | | Dufry AG | | |
50.1%
|
| |
(51.0)%
|
|
November 2019 | | | AVX Corporation | | | Kyocera Corporation | | |
44.6%
|
| |
16.3%
|
|
April 2019 | | |
Speedway Motorsports, Inc.
|
| | Sonic Financial Corporation | | |
42.0%
|
| |
8.7%
|
|
October 2018 | | | Valero Energy Partners LP | | |
Valero Energy Corporation
|
| |
6.0%
|
| |
(12.0)%
|
|
June 2018 | | | Foundation Medicine, Inc. | | | Roche Holding Ltd | | |
28.7%
|
| |
27.9%
|
|
March 2018 | | | AmTrust Financial Services, Inc. | | | Investor Group | | |
33.0%
|
| |
(51.6)%
|
|
January 2017 | | | Calamos Asset Management, Inc. | | | John Calamos | | |
12.1%
|
| |
(18.1)%
|
|
September 2016 | | | Federal-Mogul Holdings Corporation | | | Icahn Enterprises L.P. | | |
100.8%
|
| |
(28.1)%
|
|
March 2016 | | | Crown Media Holdings, Inc. | | | Hallmark Cards, Incorporated | | |
2.4%
|
| |
(16.9)%
|
|
September 2013 | | | Cornerstone Therapeutics Inc. | | | Chiesi Farmaceutici S.p.A. | | |
78.0%
|
| |
23.4%
|
|
December 2012 | | | Clearwire Corporation | | | Sprint Nextel Corporation | | |
285.0%
|
| |
N/A
|
|
November 2012 | | | Danfoss Power Solutions | | | Danfoss A/S | | |
49.0%
|
| |
5.3%
|
|
25th Percentile | | | | | | | | |
30.9%
|
| |
(18.9)%
|
|
Median | | | | | | | | |
42.0%
|
| |
(3.4)%
|
|
75th Percentile | | | | | | | | |
54.8%
|
| |
15.1%
|
|
U.S. Dollars in millions
|
| |
2022E
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |||||||||||||||
Revenue
|
| | | $ | 407 | | | | | $ | 454 | | | | | $ | 505 | | | | | $ | 561 | | | | | $ | 620 | | |
Gross Profit
|
| | | $ | 163 | | | | | $ | 180 | | | | | $ | 200 | | | | | $ | 223 | | | | | $ | 245 | | |
Adjusted EBITDA(1)
|
| | | $ | 82 | | | | | $ | 89 | | | | | $ | 100 | | | | | $ | 112 | | | | | $ | 124 | | |
Unlevered Free Cash Flow(2)
|
| | | $ | 43 | | | | | $ | 34 | | | | | $ | 54 | | | | | $ | 52 | | | | | $ | 55 | | |
Name
|
| |
Shares of
Company Common Stock Underlying Vested Options(1) |
| |
Estimated Value of
Vested Options(2) |
| |
Shares of
Company Common Stock Underlying Unvested Options(3) |
| |
Estimated Value of
Unvested Options(2) |
| ||||||||||||
Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | |
Stephen C. Farrell
|
| | | | 863,213 | | | | | $ | 2,420,747 | | | | | | 638,027 | | | | | $ | 2,386,221 | | |
Kyle Stern
|
| | | | 264,849 | | | | | $ | 800,305 | | | | | | 195,757 | | | | | $ | 732,124 | | |
John Steele
|
| | | | 264,849 | | | | | $ | 800,305 | | | | | | 195,757 | | | | | $ | 732,124 | | |
Timothy Fairbanks
|
| | | | 313,896 | | | | | $ | 948,506 | | | | | | 232,008 | | | | | $ | 867,710 | | |
Directors(4) | | | | | | | | | | | | | | | | | | | | | | | | | |
W. Carl Whitmer
|
| | | | 17,325 | | | | | $ | 10,049 | | | | | | 51,975 | | | | | $ | 30,146 | | |
Sharad Mansukani
|
| | | | 387,608 | | | | | $ | 1,322,924 | | | | | | 286,493 | | | | | $ | 1,071,484 | | |
Name
|
| |
Number of Outstanding
Company RSU Awards |
| |
Estimated Value of Outstanding
Company RSU Awards |
| ||||||
Executive Officers | | | | | | | | | | | | | |
Stephen C. Farrell
|
| | | | 355,561 | | | | | $ | 3,733,391 | | |
Kyle Stern
|
| | | | 196,231 | | | | | $ | 2,060,426 | | |
John Steele
|
| | | | 196,231 | | | | | $ | 2,060,426 | | |
Timothy Fairbanks
|
| | | | 219,711 | | | | | $ | 2,306,966 | | |
Directors(1) | | | | | | | | | | | | | |
Sharad Mansukani
|
| | | | 54,250 | | | | | $ | 569,625 | | |
Paul Campanelli
|
| | | | 27,125 | | | | | $ | 284,813 | | |
Carl Whitmer
|
| | | | 27,125 | | | | | $ | 284,813 | | |
Name
|
| |
Number of Target Company
PSU Awards(1) |
| |
Value of Company
PSU Awards(2) |
| ||||||
Executive Officers | | | | | | | | | | | | | |
Stephen C. Farrell
|
| | | | 355,561 | | | | | $ | 3,733,391 | | |
Kyle Stern
|
| | | | 108,499 | | | | | $ | 1,139,240 | | |
John Steele
|
| | | | 108,499 | | | | | $ | 1,139,240 | | |
Timothy Fairbanks
|
| | | | 146,474 | | | | | $ | 1,537,977 | | |
Directors(3) | | | | | | | | | | | | | |
Sharad Mansukani
|
| | | | 27,125(2) | | | | | $ | 284,813 | | |
Name
|
| |
Number of Shares
of Company Common Stock |
| |
Percentage of Shares
Designated as Rollover Shares |
| ||||||
Executive Officers | | | | | | | | | | | | | |
Stephen C. Farrell
|
| | | | 636,862 | | | | | | 80% | | |
Kyle Stern
|
| | | | 608,025 | | | | | | 80% | | |
John Steele
|
| | | | 750,081 | | | | | | 80% | | |
Timothy Fairbanks
|
| | | | 266,434 | | | | | | 80% | | |
Directors | | | | | | | | | | | | | |
Sharad Mansukani
|
| | | | 206,678 | | | | | | 100% | | |
All Other Rollover Shares
|
| | | | 490,261 | | | | | | 80% | | |
Description
|
| |
Amount
|
| |||
Financial advisory fees and expenses
|
| | | $ | 8,205,000 | | |
Legal, accounting and other professional fees and expenses
|
| | | $ | [•] | | |
SEC filing fees
|
| | | $ | 15,150 | | |
Printing and mailing costs
|
| | | $ | [•] | | |
Miscellaneous
|
| | | $ | [•] | | |
Total
|
| | | $ | [•] | | |
Fiscal Year
|
| |
High
|
| |
Low
|
| |
Dividend Paid
|
| |||||||||
2020 | | | | | | | | | | | | | | | | | | | |
First Quarter
|
| | | | N/A | | | | | | N/A | | | | | | — | | |
Second Quarter
|
| | | | N/A | | | | | | N/A | | | | | | — | | |
Third Quarter
|
| | | | N/A | | | | | | N/A | | | | | | — | | |
Fourth Quarter
|
| | | | N/A | | | | | | N/A | | | | | | — | | |
2021 | | | | | | | | | | | | | | | | | | | |
First Quarter
|
| | | | N/A | | | | | | N/A | | | | | | — | | |
Second Quarter
|
| | | $ | 14.29 | | | | | $ | 10.55 | | | | | | — | | |
Third Quarter
|
| | | $ | 11.48 | | | | | $ | 7.61 | | | | | | — | | |
Fourth Quarter
|
| | | $ | 8.45 | | | | | $ | 6.01 | | | | | | — | | |
2022 | | | | | | | | | | | | | | | | | | | |
First Quarter
|
| | | $ | 8.90 | | | | | $ | 4.85 | | | | | | — | | |
Second Quarter
|
| | | $ | 10.49 | | | | | $ | 3.75 | | | | | | — | | |
Third Quarter
|
| | | $ | 10.47 | | | | | $ | 10.35 | | | | | | — | | |
| | |
Shares Beneficially Owned
|
| |||||||||
Name of Beneficial Owner
|
| |
Number
|
| |
Percentage
|
| ||||||
5% Stockholders: | | | | | | | | | | | | | |
TPG Cannes Aggregation L.P.(1)
|
| | | | 54,699,513 | | | | | | 74.7% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Stephen C. Farrell(2)
|
| | | | 1,500,075 | | | | | | 2.0% | | |
John Steele(3)
|
| | | | 1,050,720 | | | | | | 1.4% | | |
Kyle Stern(4)
|
| | | | 900,774 | | | | | | 1.2% | | |
Dr. Sharad S. Mansukani(5)
|
| | | | 594,286 | | | | | | 0.8% | | |
Todd B. Sisitsky(6)
|
| | | | — | | | | | | | | |
Katherine Wood(7)
|
| | | | — | | | | | | | | |
W. Carl Whitmer(8)
|
| | | | 42,525 | | | | | | 0.1% | | |
Paul Campanelli
|
| | | | — | | | | | | | | |
All Executive Officers and Directors as a Group (9 Persons)(9)
|
| | | | 4,668,707 | | | | | | 6.4% | | |
Company Filings:
|
| |
Periods:
|
|
Annual Report on Form 10-K | | | Fiscal Year ended December 31, 2021 | |
Quarterly Report on Form 10-Q | | | Fiscal Quarter ended March 31, 2022 | |
| | |
Page
|
| |||
ARTICLE 1
The Merger; Closing; Effective Time |
| | |||||
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-2 | | | |
ARTICLE 2
Certificate of Incorporation and Bylaws of the Surviving Corporation |
| | |||||
| | | | A-2 | | | |
| | | | A-3 | | | |
ARTICLE 3
Directors and Officers of the Surviving Corporation |
| | |||||
| | | | A-3 | | | |
| | | | A-3 | | | |
ARTICLE 4
Effect of the Merger on Capital Stock; Exchange of Share Certificates |
| | |||||
| | | | A-3 | | | |
| | | | A-4 | | | |
| | | | A-6 | | | |
| | | | A-7 | | | |
ARTICLE 5
Representations and Warranties |
| | |||||
| | | | A-7 | | | |
| | | | A-22 | | | |
ARTICLE 6
Covenants |
| | |||||
| | | | A-26 | | | |
| | | | A-28 | | | |
| | | | A-31 | | | |
| | | | A-33 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-35 | | | |
| | | | A-35 | | | |
| | | | A-36 | | | |
| | | | A-36 | | | |
| | | | A-37 | | |
| | |
Page
|
| |||
| | | | A-37 | | | |
| | | | A-39 | | | |
| | | | A-40 | | | |
| | | | A-41 | | | |
| | | | A-41 | | | |
| | | | A-41 | | | |
ARTICLE 7
Conditions |
| | |||||
| | | | A-41 | | | |
| | | | A-41 | | | |
| | | | A-42 | | | |
ARTICLE 8
Termination |
| | |||||
| | | | A-42 | | | |
| | | | A-44 | | | |
ARTICLE 9
Miscellaneous and General |
| | |||||
| | | | A-45 | | | |
| | | | A-45 | | | |
| | | | A-45 | | | |
| | | | A-46 | | | |
| | | | A-46 | | | |
| | | | A-47 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-49 | | | |
| | | | A-49 | | | |
| | | | A-49 | | | |
| | | | A-50 | | | |
| | | | A-51 | | | |
| | | | A-51 | | |
|
Annex A
Defined Terms
|
| | | |
|
Exhibit A
Form of Certificate of Incorporation of the Surviving Corporation
|
| | | |
|
Exhibit B
Form of Stockholder Consent
|
| | | |
|
Exhibit C
Form of FIRPTA Certificate
|
| | | |
Term
|
| |
Section
|
|
Action | | |
5.01(h)
|
|
Agreement | | |
Preamble
|
|
Alternative Acquisition Agreement | | |
6.02(c)(iii)
|
|
Alternative Financing | | |
6.12(d)
|
|
Alternative Financing Commitment Letter | | |
6.12(d)
|
|
Applicable Date | | |
5.01(e)(i)
|
|
Bankruptcy and Equity Exception | | |
5.01(c)(i)
|
|
Book-Entry Shares | | |
4.01(a)
|
|
Bylaws | | |
2.02
|
|
Change of Recommendation | | |
6.02(c)(iii)
|
|
Charter | | |
2.01
|
|
Chosen Courts | | |
9.05(a)
|
|
Closing | | |
1.02
|
|
Closing Date | | |
1.02
|
|
Code | | |
4.02(h)
|
|
Company | | |
Preamble
|
|
Company Board | | |
Recitals
|
|
Company Disclosure Schedule | | |
5.01
|
|
Company Permits | | |
5.01(j)(ii)
|
|
Company Recommendation | | |
5.01(c)(iii)(A)
|
|
Company Reports | | |
5.01(e)(i)
|
|
Continuing Employee | | |
6.08(a)
|
|
Contract | | |
5.01(d)(ii)(C)
|
|
D&O Insurance | | |
6.10(b)
|
|
Debt Commitment Letter | | |
5.02(f)(i)
|
|
Debt Financing | | |
5.02(f)(i)
|
|
Delaware Certificate of Merger | | |
1.03
|
|
DGCL | | |
Recitals
|
|
Dissenting Shares | | |
4.01(a)
|
|
DOJ | | |
6.04(b)(iii)
|
|
DTC | | |
4.02(c)(i)
|
|
Effective Time | | |
1.03
|
|
Enforcement Costs | | |
8.02(c)
|
|
Exchange Act | | |
5.01(d)(i)(D)(2)
|
|
Excluded Benefits | | |
6.08(a)(ii)
|
|
Excluded Shares | | |
4.01(a)
|
|
FTC | | |
6.04(b)(iii)
|
|
Governmental Authority | | |
5.01(d)(i)(D)
|
|
Guarantee | | |
Recitals
|
|
Guarantors | | |
Recitals
|
|
Indemnified Parties | | |
6.10(a)
|
|
Information Statement | | |
6.03(c)(iii)
|
|
Insurance Policies | | |
5.01(r)
|
|
Intervening Event | | |
6.02(d)(ii)
|
|
IRS | | |
5.01(i)(i)(4)
|
|
Term
|
| |
Section
|
|
Laws | | |
5.01(j)(i)(A)
|
|
Letter of Transmittal | | |
4.02(c)(i)
|
|
Material Adverse Effect | | |
7.02(a)(iv)
|
|
Material Contract | | |
5.01(k)(i)
|
|
material weakness | | |
5.01(e)(ii)
|
|
Maximum Annual Premium | | |
6.10(b)
|
|
Merger | | |
Recitals
|
|
Merger Consideration | | |
4.01(a)
|
|
Merger Sub | | |
Preamble
|
|
Multiemployer Plan | | |
5.01(i)(ii)
|
|
New York Courts | | |
9.05(a)
|
|
Order | | |
7.01(b)
|
|
Outside Date | | |
8.01(b)
|
|
Parent | | |
Preamble
|
|
Parent Disclosure Schedule | | |
5.02
|
|
Parent Termination Fee | | |
8.02(c)
|
|
Parties | | |
Preamble
|
|
Paying Agent | | |
4.02(a)
|
|
Payment Fund | | |
4.02(b)
|
|
Rollover and Support Agreement | | |
Recitals
|
|
Rollover Shares | | |
Recitals
|
|
Rollover Stockholders | | |
Recitals
|
|
Preferred Stock | | |
5.01(b)(i)
|
|
Privacy Requirements | | |
5.01(q)(xi)
|
|
Professional License | | |
5.01(j)(ii)
|
|
Reimbursement Obligations | | |
6.13(d)
|
|
Schedule 13e-3 | | |
6.03(c)
|
|
Scheduled Company IP | | |
(q)5.01(q)(i)
|
|
SEC | | |
5.01(e)(i)
|
|
SEC Clearance Date | | |
6.03(d)
|
|
Securities Act | | |
5.01(d)(i)(D)(2)
|
|
service provider | | |
5.01(i)(i)
|
|
Share Certificate | | |
4.01(a)
|
|
Shares | | |
Recitals
|
|
significant deficiency | | |
5.01(e)(ii)
|
|
Special Committee | | |
Recitals
|
|
Stockholder Consent | | |
5.01(c)(iv)
|
|
Support Agreement | | |
Recitals
|
|
Surviving Corporation | | |
1.01
|
|
Takeover Statute | | |
5.01(m)
|
|
Termination Payment | | |
8.02(c)
|
|
Trade Controls | | |
5.01(j)(iv)
|
|
Unaffiliated Stockholders | | |
Recitals
|
|
WARN Act | | |
5.01(p)(ii)
|
|
| | | | COMMODORE PARENT 2022, LLC | |
| | | |
|
|
| | | | STOCKHOLDER: | |
| | | |
Number of Shares Owned (Subject Shares):
Company Equity Awards:
Number of Company Options:
Number of Company RSU Awards:
Number of Company PSU Awards:
Number of Company LTI Awards:
|
|
| | | |
JOINING PARTY:
Number of Shares Owned (Subject Shares):
Company Equity Awards:
Number of Company Options (exercisable into a number of Shares): ( )
Number of Company RSU Awards (exercisable into a number of Shares): ( )
Number of Company PSU Awards (exercisable into a number of Shares): ( )
Number of Company LTI Awards (exercisable into a number of Shares): ( )
|
|
1 Year Convey Health Solutions Chart |
1 Month Convey Health Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions